Enzymotec Ltd. (NASDAQ:ENZY) had its price objective increased by research analysts at Wells Fargo & Company from $9.50 to $12.00 in a report released on Monday, October 30th. The firm currently has a “market perform” rating on the biotechnology company’s stock. Wells Fargo & Company’s price objective would indicate a potential upside of 1.69% from the stock’s previous close.
Other equities research analysts have also issued reports about the stock. ValuEngine upgraded shares of Enzymotec from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Jefferies Group LLC restated a “hold” rating and issued a $11.50 price objective on shares of Enzymotec in a report on Thursday, October 19th. Finally, Zacks Investment Research upgraded shares of Enzymotec from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 17th. Four investment analysts have rated the stock with a hold rating, The stock currently has an average rating of “Hold” and a consensus price target of $11.75.
Enzymotec (NASDAQ:ENZY) opened at $11.80 on Monday. Enzymotec has a 12 month low of $5.20 and a 12 month high of $12.35.
Enzymotec (NASDAQ:ENZY) last released its quarterly earnings results on Wednesday, August 16th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of $0.05 by ($0.15). The company had revenue of $13.00 million during the quarter, compared to analysts’ expectations of $12.78 million. Enzymotec had a negative return on equity of 3.88% and a negative net margin of 14.52%. Enzymotec’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.04 EPS. equities analysts anticipate that Enzymotec will post 0.01 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was published by Week Herald and is owned by of Week Herald. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://weekherald.com/2017/11/15/wells-fargo-company-increases-enzymotec-ltd-enzy-price-target-to-12-00.html.
A number of large investors have recently bought and sold shares of ENZY. Janus Henderson Group PLC bought a new stake in Enzymotec during the 2nd quarter valued at $2,350,000. State Street Corp raised its holdings in Enzymotec by 1.8% in the 2nd quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock worth $169,000 after purchasing an additional 380 shares in the last quarter. Osborn Williams & Donohoe LLC bought a new position in Enzymotec in the 3rd quarter worth $137,000. Finally, JPMorgan Chase & Co. bought a new position in Enzymotec in the 3rd quarter worth $107,000. Institutional investors own 26.45% of the company’s stock.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.